TY - JOUR
T1 - Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme
AU - Harboe, Zitta B.
AU - Valentiner-Branth, Palle
AU - Benfield, Thomas
AU - Christensen, Jens Jørgen
AU - Andersen, Peter H. S.
AU - Howitz, Michael
AU - Krogfelt, Karen Angeliki
AU - Lambertsen, Lotte
AU - Konradsen, Helle B.
N1 - Keywords: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Child; Child, Preschool; Cohort Studies; Denmark; Female; Humans; Immunization Programs; Incidence; Infant; Infant, Newborn; Male; Middle Aged; Pneumococcal Infections; Pneumococcal Vaccines; Young Adult
PY - 2010/3/19
Y1 - 2010/3/19
N2 - We evaluated the effectiveness of the heptavalent pneumococcal conjugate vaccine (PCV7) on invasive pneumococcal disease (IPD) 1 year after PCV7's introduction in the childhood immunization programme through a nationwide cohort study based on laboratory surveillance data. There was a decline in the overall incidence of IPD from 19.4 to 17.1 cases per 100,000 population (incidence rate ratios (IRR) 0.87; 95% confidence interval (CI) [0.81-0.96]), and of meningitis from 1.56 to 1.16 (IRR 0.74; 95% CI [0.57-0.97]) comparing pre-PCV7 (years 2000-2007) and PCV7 (year 2008) periods. In children <2 years, the incidence decreased from 54 to 23 cases per 100,000 (IRR 0.43; 95% CI [0.29-0.62]) and for vaccine-serotypes from 36.7 to 7.7 (IRR 0.20; 95% CI [0.09-0.38]). The incidence of IPD declined ∼10% (IRR 0.90; 95% CI [0.84-0.97]) in patients aged ≥2 years. The case fatality was 17% in both periods. The administration of PCV7 was followed by a marked decline in the incidence of IPD in both vaccinated and non-vaccinated individuals.
AB - We evaluated the effectiveness of the heptavalent pneumococcal conjugate vaccine (PCV7) on invasive pneumococcal disease (IPD) 1 year after PCV7's introduction in the childhood immunization programme through a nationwide cohort study based on laboratory surveillance data. There was a decline in the overall incidence of IPD from 19.4 to 17.1 cases per 100,000 population (incidence rate ratios (IRR) 0.87; 95% confidence interval (CI) [0.81-0.96]), and of meningitis from 1.56 to 1.16 (IRR 0.74; 95% CI [0.57-0.97]) comparing pre-PCV7 (years 2000-2007) and PCV7 (year 2008) periods. In children <2 years, the incidence decreased from 54 to 23 cases per 100,000 (IRR 0.43; 95% CI [0.29-0.62]) and for vaccine-serotypes from 36.7 to 7.7 (IRR 0.20; 95% CI [0.09-0.38]). The incidence of IPD declined ∼10% (IRR 0.90; 95% CI [0.84-0.97]) in patients aged ≥2 years. The case fatality was 17% in both periods. The administration of PCV7 was followed by a marked decline in the incidence of IPD in both vaccinated and non-vaccinated individuals.
U2 - 10.1016/j.vaccine.2010.01.017
DO - 10.1016/j.vaccine.2010.01.017
M3 - Journal article
C2 - 20096392
SN - 0264-410X
VL - 28
SP - 2642
EP - 2647
JO - Vaccine
JF - Vaccine
IS - 14
ER -
